FDA grants fast review to BMS’ first-line lung cancer comboBristol-Myers Squibb has finally made its bid for a slice of the lucrative first-line lung non-small cell lung Share XFDA grants fast review to BMS’ first-line lung cancer combohttps://pharmaphorum.com/news/fda-grants-fast-review-to-bms-first-line-lung-cancer-combo/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Brisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerBristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and Share XBrisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerhttps://pharmaphorum.com/news/celgene-shareholders/
BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomaBristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, Share XBMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomahttps://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/
$74bn BMS/Celgene merger finally cleared by competition regulatorsBristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 Share X$74bn BMS/Celgene merger finally cleared by competition regulatorshttps://pharmaphorum.com/news/74bn-bms-celgene-merger-finally-cleared-by-competition-regulators/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
BMS gets a much-needed win with Opdivo in first-line lung cancerBristol-Myers Squibb’s attempts to challenge Merck & Co’s dominance in previously-untreated non-small cell lung cancer (NSCLC) have disappointed Share XBMS gets a much-needed win with Opdivo in first-line lung cancerhttps://pharmaphorum.com/news/bms-gets-a-much-needed-win-with-opdivo-in-first-line-lung-cancer/
BMS’ Opdivo misses target in aggressive brain cancer trialIt’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Share XBMS’ Opdivo misses target in aggressive brain cancer trialhttps://pharmaphorum.com/news/bms-opdivo-off-target-in-aggressive-brain-cancer/
